1型糖尿病遗传风险评分可识别GAD65抗体阳性2型糖尿病中快速进展至胰岛素治疗的患者
本研究在8608例临床诊断2型糖尿病(发病年龄>35岁且至少6个月未用胰岛素)患者中,分析1型糖尿病遗传风险评分(T1D GRS)与GAD65自身抗体(GADA)对5年内快速需要胰岛素治疗的预测价值。结果显示,在GADA阳性(3.3%)患者中,T1D GRS越高,5年内需要胰岛素治疗的概率越高(高T1D GRS 47.9% vs 中T1D GRS 27.6% vs 低T1D GRS 17.6%;P=0.001),而GADA阴性者中T1D GRS无预测作用(P=0.4)。校正年龄、BMI和队列后,仅在GADA阳性者中T1D GRS独立与胰岛素时间相关(每SD风险比1.48;95%CI 1.15-1.90;P=0.002)。
要点
- 在临床诊断2型糖尿病且GADA阳性患者中,T1D GRS高者5年内胰岛素需求概率显著更高。
- GADA阴性患者中T1D GRS不能预测快速进展至胰岛素治疗。
- T1D GRS可独立于年龄、BMI等临床特征,增强GADA阳性对胰岛素需求的预测。
核心结论
- T1D GRS可改变临床诊断2型糖尿病患者GADA阳性结果的临床意义,且独立于并附加于临床特征。
研究设计与样本
- 在8608例临床诊断2型糖尿病(发病年龄>35岁且至少6个月未用胰岛素)患者中,采用Kaplan-Meier生存分析和Cox回归分析T1D GRS、GADA与5年内快速需要胰岛素治疗的关系。
- T1D GRS既作为标准化评分连续分析,也根据既往报道的1型糖尿病队列百分位数分为低(<第5百分位)、中(第5-50百分位)和高(>第50百分位)三组。
主要发现
- GADA阳性参与者占3.3%,其5年内需要胰岛素治疗的概率(95%CI)随T1D GRS升高而增加:高T1D GRS 47.9%(35.0%,62.78%),中T1D GRS 27.6%(20.5%,36.5%),低T1D GRS 17.6%(11.2%,27.2%);P=0.001。
- 在GADA阴性参与者中,T1D GRS不能预测快速胰岛素需求(P=0.4)。
- 校正诊断年龄、BMI和队列后,仅在GADA阳性者中T1D GRS独立与胰岛素时间相关:每SD增加的风险比1.48(1.15,1.90);P=0.002。
临床怎么用
- 对于临床诊断2型糖尿病且GADA阳性患者,可结合T1D GRS评估5年内快速进展至胰岛素治疗的风险,高分者可能需更密切监测和早期胰岛素治疗准备。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Progression to insulin therapy in clinically diagnosed type 2 diabetes is highly variable. GAD65 autoantibodies (GADA) are associated with faster progression, but their predictive value is limited. We aimed to determine if a type 1 diabetes genetic risk score (T1D GRS) could predict rapid progression to insulin treatment over and above GADA testing. RESEARCH DESIGN AND METHODS: We examined the relationship between T1D GRS, GADA (negative or positive), and rapid insulin requirement (within 5 years) using Kaplan-Meier survival analysis and Cox regression in 8,608 participants with clinical type 2 diabetes (onset >35 years and treated without insulin for ≥6 months). T1D GRS was both analyzed continuously (as standardized scores) and categorized based on previously reported centiles of a population with type 1 diabetes (<5th [low], 5th-50th [medium], and >50th [high]). RESULTS: In GADA-positive participants (3.3%), those with higher T1D GRS progressed to insulin more quickly: probability of insulin requirement at 5 years (95% CI): 47.9% (35.0%, 62.78%) (high T1D GRS) vs. 27.6% (20.5%, 36.5%) (medium T1D GRS) vs. 17.6% (11.2%, 27.2%) (low T1D GRS); P = 0.001. In contrast, T1D GRS did not predict rapid insulin requirement in GADA-negative participants (P = 0.4). In Cox regression analysis with adjustment for age of diagnosis, BMI, and cohort, T1D GRS was independently associated with time to insulin only in the presence of GADA: hazard ratio per SD increase was 1.48 (1.15, 1.90); P = 0.002. CONCLUSIONS: A T1D GRS alters the clinical implications of a positive GADA test in patients with clinical type 2 diabetes and is independent of and additive to clinical features.
引用
- Grubb AL, McDonald TJ, Rutters F, et al. A Type 1 Diabetes Genetic Risk Score Can Identify Patients With GAD65 Autoantibody-Positive Type 2 Diabetes Who Rapidly Progress to Insulin Therapy. Diabetes Care. 2018. PMID: 30352895. doi:10.2337/dc18-0431
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。